+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020

  • PDF Icon

    Report

  • 318 Pages
  • November 2020
  • Region: Global
  • GlobalData
  • ID: 5212228
Summary

The publisher's Medical Devices sector report, “Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Lung Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Lung Cancer Diagnostic Tests include assays of mostly antibodies released in response to a lung cancer and cancer-causing proteins.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Lung Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Lung Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Lung Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Lung Cancer Overview
3 Products under Development
3.1 Lung Cancer - Pipeline Products by Stage of Development
3.2 Lung Cancer - Pipeline Products by Territory
3.3 Lung Cancer - Pipeline Products by Regulatory Path
3.4 Lung Cancer - Pipeline Products by Estimated Approval Date
3.5 Lung Cancer - Ongoing Clinical Trials
4 Lung Cancer - Pipeline Products under Development by Companies
4.1 Lung Cancer Companies - Pipeline Products by Stage of Development
4.2 Lung Cancer - Pipeline Products by Stage of Development
5 Lung Cancer Companies and Product Overview6 Lung Cancer- Recent Developments
7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact
7.4 Disclaimer
List of Tables
Table 1: Lung Cancer - Pipeline Products by Stage of Development
Table 2: Lung Cancer - Pipeline Products by Territory
Table 3: Lung Cancer - Pipeline Products by Regulatory Path
Table 4: Lung Cancer - Pipeline Products by Estimated Approval Date
Table 5: Lung Cancer - Ongoing Clinical Trials
Table 6: Lung Cancer Companies - Pipeline Products by Stage of Development
Table 7: Lung Cancer - Pipeline Products by Stage of Development
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Onco 88 - Lung Cancer - Product Status
Table 10: Onco 88 - Lung Cancer - Product Description
Table 11: OncoStain 88 - Lung Cancer - Product Status
Table 12: OncoStain 88 - Lung Cancer - Product Description
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 14: Alinity i Assay - NSE - Product Status
Table 15: Alinity i Assay - NSE - Product Description
Table 16: ARCHITECT c4000 System - NSE Assay - Product Status
Table 17: ARCHITECT c4000 System - NSE Assay - Product Description
Table 18: ARCHITECT c8000 System - NSE Assay - Product Status
Table 19: ARCHITECT c8000 System - NSE Assay - Product Description
Table 20: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status
Table 21: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description
Table 22: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status
Table 23: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description
Table 24: ARCHITECT i1000SR System - NSE Assay - Product Status
Table 25: ARCHITECT i1000SR System - NSE Assay - Product Description
Table 26: ARCHITECT i2000SR System - Neuron-Specific Enolase Assay - Product Status
Table 27: ARCHITECT i2000SR System - Neuron-Specific Enolase Assay - Product Description
Table 28: PRAME Antigen Lung Cancer Assay - Product Status
Table 29: PRAME Antigen Lung Cancer Assay - Product Description
Table 30: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Diagnostic Assay - Lung Cancer - Product Status
Table 32: Diagnostic Assay - Lung Cancer - Product Description
Table 33: MCM Test - Lung Cancer - Product Status
Table 34: MCM Test - Lung Cancer - Product Description
Table 35: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Diagnostic Biomarker Test - Lung Cancer - Product Status
Table 37: Diagnostic Biomarker Test - Lung Cancer - Product Description
Table 38: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 39: Diagnostic Test - ACTN4 - Product Status
Table 40: Diagnostic Test - ACTN4 - Product Description
Table 41: Acobiom Pipeline Products & Ongoing Clinical Trials Overview
Table 42: Companion Diagnostic Test - Lung Cancer - Product Status
Table 43: Companion Diagnostic Test - Lung Cancer - Product Description
Table 44: Diagnostic/Prognostic Assay - Lung Cancer - Product Status
Table 45: Diagnostic/Prognostic Assay - Lung Cancer - Product Description
Table 46: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview
Table 47: DiagnoLung - Product Status
Table 48: DiagnoLung - Product Description
Table 49: Predictive Diagnostic Test - Lung Cancer - Product Status
Table 50: Predictive Diagnostic Test - Lung Cancer - Product Description
Table 51: Prognostic Test - Lung Cancer - Product Status
Table 52: Prognostic Test - Lung Cancer - Product Description
Table 53: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 54: Biomarker Assay - Lung Cancer - Product Status
List of Figures
Figure 1: Lung Cancer - Pipeline Products by Stage of Development
Figure 2: Lung Cancer - Pipeline Products by Territory
Figure 3: Lung Cancer - Pipeline Products by Regulatory Path
Figure 4: Lung Cancer - Pipeline Products by Estimated Approval Date
Figure 5: Lung Cancer - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • A&G Pharmaceutical Inc
  • Abbott Diagnostics
  • Abcodia Ltd
  • Aberystwyth University
  • Abnova Corp
  • Acobiom
  • Advanced Marker Discovery SL
  • AIT Austrian Institute of Technology GmbH
  • Almac Diagnostic Services Ltd
  • Anixa Diagnostics Corporation
  • Armune BioScience Inc
  • Aurelium BioPharma Inc.
  • Avant Diagnostics Inc
  • BARD1 Life Sciences Ltd
  • BioAffinity Technologies, Inc.
  • Biocept Inc
  • Biodesix Inc
  • Biological Dynamics Inc
  • BioMark Diagnostics Inc
  • BioMarker Strategies LLC
  • BioNTech SE
  • BioSystems International
  • Boston Children's Hospital
  • Cancer Genetics Inc
  • Cancer Research Technology Ltd
  • Cangen Biotechnologies Inc (Inactive)
  • CDI Laboratories Inc
  • Celcuity Inc
  • Cellanyx Diagnostics, Inc.
  • Cellmid Ltd
  • CeMines, Inc. (Inactive)
  • Cepheid Inc
  • Ceres Nanosciences Inc
  • Cernostics Inc
  • ChemImage Corp
  • Clarient Inc
  • Courtagen Life Sciences Inc
  • Creatv MicroTech Inc
  • DiagnoCure Inc. (Inactive)
  • EDP Biotech Corporation
  • Emory University
  • Enterome Bioscience SA
  • Entopsis LLC
  • Epic Sciences Inc
  • Epigenomics AG
  • Eventus Diagnostics Inc (Inactive)
  • Exact Sciences Corp
  • Exiqon AS
  • Exosome Diagnostics Inc
  • Exosomics Siena SpA
  • Fahy Gurteen UK Ltd
  • FibroStatin SL
  • Fina Biotech SL
  • French National Institute of Health and Medical Research
  • Gene Express, Inc. (Inactive)
  • GeneCentric Diagnostics, Inc.
  • Genome Profiling LLC
  • Global Discovery Biosciences Corporation
  • GlycoZym USA Inc
  • Guardant Health Inc
  • ImmunePharma Srl
  • ImmunoCellular Therapeutics Ltd
  • Immunovia AB
  • Insight Genetics Inc
  • InterGenetics Inc
  • Louisville Bioscience Inc (Inactive)
  • Massachusetts General Hospital
  • Mayo Clinic
  • MDNA Life Sciences Inc
  • MDxHealth SA
  • MEDITE Cancer Diagnostics Inc
  • Memory Dx LLC
  • Merrimack Pharmaceuticals Inc
  • Metabolon Inc
  • Metanomics Health GmbH
  • MetaStat Inc
  • Milagen Inc
  • Myriad International GmbH
  • Nagoya University
  • Nanocytomics LLC
  • Nanostics Inc
  • NEOMICS Co Ltd
  • NovaGray
  • Novel Bio-spectrum Technologies Inc (Inactive)
  • Oncimmune (USA) LLC
  • OncoCyte Corp
  • Oncolome Diagnostics Inc (Inactive)
  • Onconome, Inc. (Inactive)
  • OncoStem Diagnostics Pvt. Ltd
  • OPKO Health Inc
  • Orion Genomics LLC
  • OTraces Inc
  • Peri Rx Inc
  • PleX Diagnostics Inc (Inactive)
  • PreMD Inc (Inactive)
  • Proplex Technologies Llc
  • Proteome Sciences Plc
  • Proteomika (Inactive)
  • Quanterix Corp
  • Queensland University of Technology
  • Research Center Borstel
  • Roche Diagnostics International Ltd
  • Rosetta Genomics Ltd
  • Roswell Park Cancer Institute
  • Savicell Diagnostic Ltd.
  • Sengenics Corp Pte Ltd
  • Shenzhen Mindray Bio-Medical Electronics Co Ltd
  • Siemens Healthcare Diagnostics Inc
  • Sienna Cancer Diagnostics Ltd
  • Simon Fraser University
  • SomaLogic Inc
  • Southern Illinois University Carbondale
  • Sysmex Corp
  • Taizhou ZECEN Biotech Co Ltd
  • The Prince Charles Hospital
  • Thermo Fisher Scientific Inc
  • Transgene SA
  • Treos Bio Inc
  • Universal Diagnostics SL
  • University of California San Francisco
  • University of Chicago
  • University of Colorado
  • University of Maryland
  • University of Queensland
  • University of South Florida
  • University of Texas MD Anderson Cancer Center
  • US Biomarkers Inc
  • Vanderbilt University
  • Ventana Medical Systems Inc
  • Viomics Inc.
  • VisionGate Inc
  • VolitionRX Ltd
  • XEPTAGEN SpA
  • Zetiq Technologies Ltd
  • ZORA Biosciences Oy